Spots Global Cancer Trial Database for Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer
Official Title: A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients With Differentiated Thyroid Cancer
Study ID: NCT01843062
Conditions
Study Description
Brief Summary: The study is designed to evaluate the clinical efficacy, safety and tolerability of selumetinib with radioactive iodine therapy in patients with differentiated thyroid cancer.
Detailed Description: A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients with Differentiated Thyroid Cancer.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research Site, Birmingham, Alabama, United States
Research Site, Little Rock, Arkansas, United States
Research Site, Los Angeles, California, United States
Research Site, Torrance, California, United States
Research Site, Aurora, Colorado, United States
Research Site, Washington, District of Columbia, United States
Research Site, Boston, Massachusetts, United States
Research Site, Boston, Massachusetts, United States
Research Site, New York, New York, United States
Research Site, New York, New York, United States
Research Site, Durham, North Carolina, United States
Research Site, Cincinnati, Ohio, United States
Research Site, Portland, Oregon, United States
Research Site, Philadelphia, Pennsylvania, United States
Research Site, Nashville, Tennessee, United States
Research Site, Barretos, , Brazil
Research Site, Porto Alegre, , Brazil
Research Site, Ribeirão Preto, , Brazil
Research Site, Rio de Janeiro, , Brazil
Research Site, São José do Rio Preto, , Brazil
Research Site, São Paulo, , Brazil
Research Site, Odense C, , Denmark
Research Site, Angers Cedex 01, , France
Research Site, Bordeaux Cedex, , France
Research Site, Caen Cedex 5, , France
Research Site, Lyon, , France
Research Site, Toulouse Cedex 9, , France
Research Site, Villejuif Cedex, , France
Research Site, Augsburg, , Germany
Research Site, Essen, , Germany
Research Site, Leipzig, , Germany
Research Site, Catania, , Italy
Research Site, Napoli, , Italy
Research Site, Pisa, , Italy
Research Site, Roma, , Italy
Research Site, Gliwice, , Poland
Research Site, Kielce, , Poland
Research Site, Poznań, , Poland
Research Site, Warszawa, , Poland
Research Site, Warszawa, , Poland
Research Site, Zgierz, , Poland
Research Site, Göteborg, , Sweden
Research Site, Linköping, , Sweden
Research Site, Lund, , Sweden
Research Site, Stockholm, , Sweden
Contact Details
Name: Alan Ho, M.D., PHD
Affiliation: Memorial Sloan Kettering Cancer Centre, 1275 York Avenue, New York, NY 10065.
Role: PRINCIPAL_INVESTIGATOR
Name: Tracy C Cunningham, M.D
Affiliation: Melbourn Science Park, Cambridge Road, Melbourn, Hertfordshire, SG8 6HB, UK
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
